01.24.2022
In December the FDA authorized Evusheld, a long-acting monoclonal antibody for prevention of COVID-19 in immunocompromised individuals 12 years or older, or individuals unable to tolerate any COVID-19 vaccination. Evusheld is NOT intended for those who have no contraindication to vaccination and are choosing not to be vaccinated.
Evusheld may be less active against certain Omicron subvariants.
Evusheld is available at regional MHC infusion clinics in Cadillac, Frankfort, Grayling, Kalkaska, Manistee, and Traverse City.
How to Refer Tier 1 and 2 Patients for Evusheld
- Primary care providers are encouraged to refer patients who meet Tier 1 and 2 eligibility criteria and who would like to receive Evusheld therapy by faxing the patient’s most recent office note, demographics/insurance information, and the Evusheld referral form to 231-392-7348.
- Please read the FDA Fact Sheet — including the warnings and precautions specific to hypersensitivity reactions, the risk of cross-hypersensitivity with COVID-19 vaccines, clinically significant bleeding disorders, and cardiovascular events — prior to prescribing Evusheld.
- Although a higher proportion of subjects who received Evusheld vs. placebo reported myocardial infarction and cardiac failure serious adverse events, all of the subjects with events had cardiac risk factors and/or a prior history of cardiovascular disease, and there was no clear temporal pattern.
- There was a low number of subjects who experienced a cardiac event: 0.6% in treatment arm vs. 0.2% in placebo arm.
- A causal relationship between Evusheld and these events has not been established.
- Consider the risks and benefits prior to initiating Evusheld in individuals at high risk for cardiovascular events, and advise individuals to seek immediate medical attention if they experience any signs or symptoms suggestive of a cardiovascular event.
- As patient self-referral is NOT available at this time, please do not direct patients to call to be scheduled.
- After receiving a provider’s referral, the mAb/Evusheld Therapy Team will contact eligible patients to schedule an appointment.
- Questions? Email the mAb Support Team.
Resources